title: Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
abstract: Tumor-treating fields (TTFields) is a novel antimitotic treatment modality for patients with glioblastoma. To assess response to TTFields, a newly diagnosed patient with glioblastoma underwent diffusion, perfusion and 3D echo-planar spectroscopic imaging prior to initiation of TTFields plus temozolamide (baseline) and at 1- and 2-month follow-up periods. Increased mean diffusivity along with decreased fractional anisotropy and maximum relative cerebral blood volume were noted at 2 months relative to baseline suggesting inhibition of tumor growth and angiogenesis. Additionally, a reduction in choline/creatine was also noted during this period. These preliminary data indicate the potential of physiologic and metabolic MRI in assessing early treatment response to TTFields in combination with temozolamide.
authors.affiliation: Departments of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Suyash
authors.initials: S
authors.lastname: Mohan
authors.affiliation: Departments of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Chawla
authors.affiliation: Departments of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Sumei
authors.initials: S
authors.lastname: Wang
authors.affiliation: Departments of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Gaurav
authors.initials: G
authors.lastname: Verma
authors.affiliation: Departments of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Aaron
authors.initials: A
authors.lastname: Skolnik
authors.affiliation: Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Brem
authors.affiliation: The Preston Robert Tisch Brain Tumor Center, Department of Neurology, Duke University Medical Center, Durham, NC, USA.
authors.forename: Katherine B
authors.initials: KB
authors.lastname: Peters
authors.affiliation: Departments of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.|Department of Cellular & Molecular Physiology, University of Liverpool, Liverpool, UK.
authors.forename: Harish
authors.initials: H
authors.lastname: Poptani
mesh_terms: D016880:Anisotropy; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D000071937:Cerebral Blood Volume / Q000187:drug effects / Q000502:physiology; D002794:Choline / Q000378:metabolism; D003401:Creatine / Q000378:metabolism; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004599:Electric Stimulation Therapy; D004574:Electromagnetic Fields; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods*; D000077204:Temozolomide; D013788:Thalamus / Q000000981:diagnostic imaging
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D003401:Creatine; D002794:Choline; D000077204:Temozolomide
keywords: diffusion tensor imaging; echo-planar spectroscopic imaging; glioblastoma; perfusion-weighted imaging; therapeutic response; tumor-treating fields